Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Iimatinib Mesylate Market in China 2021
15 March 2021
The iImatinib mesylate market in China in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 22.9% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for iImatinib mesylate. The China iImatinib mesylate market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.
The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Hansoh Pharmaceutical Group Company Limited, Novartis International AG.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the iImatinib mesylate market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Region: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China iImatinib mesylate market
Pinpoint growth sectors and trends for investment
Understand what the future of the iImatinib mesylate market in China looks like
Identify the competitive landscape and window of opportunity
Table of Contents
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Iimatinib Mesylate Market by Region
4.1 Central South China
4.2 East China
4.3 North China
4.4 Northeast China
4.5 Northwest China
4.6 Southwest China
5. Company Profiles
5.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.2 Hansoh Pharmaceutical Group Company Limited
5.3 Novartis International AG
6.1 About StrategyHelix